662 related articles for article (PubMed ID: 17052297)
1. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
2. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
[TBL] [Abstract][Full Text] [Related]
3. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
5. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
8. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
[TBL] [Abstract][Full Text] [Related]
9. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
[TBL] [Abstract][Full Text] [Related]
11. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
12. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
13. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
[TBL] [Abstract][Full Text] [Related]
14. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
15. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
[TBL] [Abstract][Full Text] [Related]
19. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
20. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Corrigan D; Paton J
Pediatr Pulmonol; 1999 Jan; 27(1):37-42. PubMed ID: 10023790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]